1
|
Bilic Z, Gojkovic S, Kalogjera L, Krezic I, Malekinusic D, Knezevic M, Sever M, Lojo N, Kokot A, Kasnik K, Kralj T, Vukojevic J, Siroglavic M, Peklic M, Drmic D, Milavic M, Sikiric S, Skorak I, Brizic I, Hriberski K, Kubat M, Vladic J, Boban Blagaic A, Tvrdeic A, Skrtic A, Seiwerth S, Sikiric P. Novel insight into Robert's cytoprotection: complex therapeutic effect of cytoprotective pentadecapeptide pentadecapeptide BPC 157 in rats with perforated stomach throughout modulation of nitric oxide-system. Comparison with L-arginine, ranitidine and pantoprazole therapy and L-N G-nitro-L-arginine methyl ester worsening. J Physiol Pharmacol 2021; 72. [PMID: 35485358 DOI: 10.26402/jpp.2021.6.11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 09/21/2021] [Accepted: 12/31/2021] [Indexed: 06/14/2023]
Abstract
Surgically perforated stomach (since direct injury in rats until persisting defect and huge adhesions (day 1, day 7)) fairly represent an unresolved cytoprotection issue, and thereby, we focused resolving of the immediate triad, particular vascular failure (vessels 'disappear'/empty), prolonged bleeding, debilitated defect large widening. Agents (mg/kg) or saline (controls) were given at 1 min post-injury as an abdominal bath (10 ml/rat throughout 2 min). Within 1 - 15 min post-injury period, with cytoprotective BPC 157 (0.01 μg), the rapidly restored vessels 'run' (vessels filled/reappeared) toward the perforated defect, and there is less bleeding, and defect contraction; advanced perforated lesion healing (day 1) to complete healing (day 7), and less adhesions. With pantoprazole (10 mg), early (vessels (worsening), bleeding (prolongation), defect (attenuated widening)) effect means eventual lesions and adhesions severity as in controls. Ranitidine (10 mg) early effect (vessels (improvement), bleeding (less bleeding), defect (eliminated widening, defect not changed)) means final lesions attenuation, but not complete healing, less adhesions. L-NAME (5 mg) early (vessels worsening, less bleeding, attenuated defect widening) and final (lesions aggravation, more adhesions) effect, versus L-arginine (100 mg) early (vessels improvement, more bleeding, attenuated defect widening) and final (lesions attenuation, less adhesions) effect, combined few simultaneously occurring nitric oxide (NO)-system distinct processes. Finally, in the stomach tissue surrounding defect, increased malondialdehyde (MDA)- and decreased NO-values, BPC 157 reversed to the normal healthy values, and mRNA expression studies (Cox2, VEGFa, Nos1, Nos 2, Nos3, Nkap (NF-kappa-B-activating protein gene)), done at that very early post-perforation-time, indicate a way how BPC 157 may act beneficially in the perforated stomach lesion throughout NO- and prostaglandinds-system.
Collapse
Affiliation(s)
- Z Bilic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - S Gojkovic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - L Kalogjera
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - I Krezic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - D Malekinusic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - M Knezevic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - M Sever
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - N Lojo
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - A Kokot
- Department of Anatomy and Neuroscience, Faculty of Medicine, J.J. Strossmayer University of Osijek, Osijek, Croatia
| | - K Kasnik
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - T Kralj
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - J Vukojevic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - M Siroglavic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - M Peklic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - D Drmic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - M Milavic
- Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - S Sikiric
- Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - I Skorak
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - I Brizic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - K Hriberski
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - M Kubat
- Department of Forensic Medicine and Criminology, School of Medicne, Zagreb, Croatia
| | - J Vladic
- Laboratory for Advanced Genomics, Division of Molecular Medicine, Institute Ruder Boskovic, Zagreb, Croatia
| | - A Boban Blagaic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - A Tvrdeic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - A Skrtic
- Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia.
| | - S Seiwerth
- Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - P Sikiric
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia.
| |
Collapse
|